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Hepatitis  C is  an  important  cause  of  chronic  liver  disease  worldwide  with  an estimated  170 million
people  infected.  Hepatitis  C virus  (HCV)-infected  patients  are physically  and mentally  impacted  by  fatigue,
depression  and  anxiety  causing  an  impairment  of  health  related  quality  of  life  (HRQOL),  lower  worker
productivity  and other  patient  reported  outcomes  (PROs).  Although  anti-HCV  regimens  containing  ﬁrst
generation  direct  acting  antiviral  agents  (DAAs)  were  associated  with  signiﬁcant  side  effects,  the second
generation  DAAs,  sofosbuvir  (SOF)  and  simeprevir  (SMV),  are  associated  with  fewer  side effects,  better
tolerability  and  high  cure  rates.
Despite these  advantages,  key  stakeholders  are  currently  trying  to  ﬁnd  ways  to  best integrate  these
new  therapeutic  regimens  into  the management  of  patients  with  chronic  hepatitis  C  for  the  beneﬁt  of all.
The  purpose  of this  article  is to offer  insight  into  the  other  key  and  equally  important  outcomes  (PRO’s,
HRQOL  and  cost)  which  should  be  considered  when  assessing  the  applicability  of  these  new  regimens  for
the  care  of  patients  infected  with  HCV.
Our review  provides  evidence  that  the  new  treatment  regimens  for HCV  not only  have  high  efﬁcacy
rates  but  are  also associated  with  better  patient  reported  outcomes  and  cost  per case of HCV  cured.
Additionally,  compared  to other medical  interventions,  these  new  regimens  are  cost-effective  from  a
societal  perspective.
© 2014  Published  by  Elsevier  Ltd on  behalf  of Editrice  Gastroenterologica  Italiana  S.r.l.
Open access under CC BY-NC-ND license.. Introduction
The new treatment of chronic hepatitis C (CH-C), a prominent
nd potentially devastating liver disease worldwide, is evolving
nd promises higher cure rates with fewer side effects and shorter
reatment duration [1–4]. Until recently, a triple therapy (TT)
ombination of the drugs which included pegylated interferon-
lfa (PEG-IFN), ribavirin (RBV) and the ﬁrst generation protease
nhibitors [telaprevir (TVR) and boceprevir (BOC)] was the stan-
ard of care for treating chronic hepatitis C (CH-C) [2]. However,
n late 2013, two  new regimens were approved. The ﬁrst regimen
ncluded sofosbuvir (SOF) which was given in combination with rib-
virin with or without pegylated interferon. The second regimen
as a triple combination of simeprevir, pegylated interferon and
∗ Corresponding author at: Betty and Guy Beatty Center for Integrated Research,
laude  Moore Health Education and Research Building, 3300 Gallows Road, Falls
hurch, VA 22042, USA. Tel.: +1 703 776 2540; fax: +1 703 776 4386.
E-mail  address: zobair.younossi@inova.org (Z. Younossi).
ttp://dx.doi.org/10.1016/j.dld.2014.09.025
590-8658/© 2014 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italribavirin for HCV genotype 1 patients [3,4]. The use of these agents,
the exact regimen and their indications are covered elsewhere in
this supplement.
Since these new treatments have been approved, there has been
a great deal of debate about the cost of the medication and who
should receive this treatment [5]. Unfortunately, these debates
have overshadowed the remarkable advances that these drugs have
provided to the patients with CH-C. In addition to their high efﬁ-
cacy rates and better tolerability, these regimens are simple to use
and improve outcomes that are important to patients (PROs). Fur-
thermore, when one considers the entire cost of HCV and the total
cost of treatment episodes, these new regimens are associated with
better cost per cure as well as incremental cost-effectiveness ratios.
To better understand the total impact of these regimens on
clinical, economic and patient-reported outcomes, we are present-
ing evidence from 2 additional angles – one regarding the impact
of HCV treatment on patient-reported outcomes (PROs), and the
second on the economic aspect of treating HCV. It is critical that
these two key components are also considered when deciding on
the appropriateness of a curative drug therapy. Since there are no
iana S.r.l. Open access under CC BY-NC-ND license.
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ublished PRO data related to the triple combination of simeprevir
SIM), pegylated interferon and ribavirin or other investigational
egimens, this article focuses only historical regimens with IFN
nd RBV and on SOF-containing regimens.
. What are patient reported outcomes?
Patient reported outcomes are deﬁned as measurements that
re based on reports that come directly from the patient about the
tatus of their health condition without amendment or interpre-
ation by a clinician or anyone else [6]. In clinical research, it has
ecome increasingly important to capture PRO data. In this context,
dding PRO assessment to the clinical outcomes provides the most
omplete assessment of the impact of a chronic disease such as CH-
 and its treatment. There are a number of important PROs that pro-
ide insight into patients’ experiences. Here, we will focus on health
elated quality of life (HRQOL), fatigue and work productivity.
HRQOL falls under the broader category of Quality-of-Life which
ccounts for many other aspects of a person’s life, including the
nﬂuence of environment, freedom, economy as well as aspects
f individual’s culture, values, and spirituality [6–10]. On the
ther hand, HRQOL speciﬁcally deals with the impact of health
n patients’ well-being and is very succinctly deﬁned as a broad
ultidimensional concept that includes self-reported measures of
hysical and mental health as well as the ability to be socially active
social well-being) [6–20].
Although  the terms HRQOL and patient reported outcomes
PRO’s) have been used interchangeably, PROs include other out-
omes reported by and important to patients [21–24].
In  general, HRQOL tools or instruments are divided into General
easures (generic HRQOL instruments) and disease speciﬁc HRQOL
nstruments [6–24]. These instruments have been developed and
alidated carefully. Modular instruments, based on generic instru-
ents with some disease-speciﬁc modules, are typically developed
y industry to assess HRQOL in their clinical trials. Health utility
s another type of assessment used which determines a patient’s
reference for a state of health [25–27]. Health utilities can be
ssessed indirectly (example: Health Utility Index Mark 1 and 2)
r directly (Standard gamble, Time-Trade-Off). Health utilities are
ypically used in cost effectiveness analysis to quality adjust out-
omes and provide quality adjusted years of life (QALYs) to compare
ifferent interventions [25–27]. In the following paragraphs, we
escribe the HRQOL/PRO instruments used in the clinical trials of
OF-containing regimens.
The  Short Form-36 version 2 (SF-36v2) is a widely used generic
nstrument for HRQOL evaluation [21]. It assesses eight HRQOL
cales (ranging 0–100 with higher values corresponding to a better
ealth status): physical functioning (PF), role physical (RP), bodily
ain (BP), general health (GH), vitality (VT), social functioning (SF),
ole emotional (RE), and mental health (MH). The two summary
cores summarize the physical and mental health components of
F-36: the Physical Component Summary score (PCS) and Men-
al Component Summary score (MCS). Scores can be compared to
stablished U.S. population norms [21]. SF-36 has been extensively
sed in studying a number of chronic diseases, including CH-C.
n addition to SF-36, there are a number of other generic HRQOL
nstruments such as sickness impact proﬁle (SIP) and EuroQual
EQ5D) which have been used in patients with CH-C [19,20].
The  CLDQ-HCV is another widely used and validated HRQOL
nstrument developed speciﬁcally for assessment of HRQOL in HCV
atients [14,20,22]. The CLDQ-HCV includes four HRQOL domains:
ctivity and energy (AE), emotional (EM), worry (WO), and systemic
SY). There are domain scores and total CLDQ-HCV score which
anges 1–7 with higher values representing better HRQOL [14,22].
lthough modular HRQOL instruments have been developed for
linical trials of HCV, CLDQ-HCV is the only disease-speciﬁc HRQOLer Disease 46 (2014) S186–S196 S187
instrument  that has been speciﬁcally developed for patients with
CH-C.
The Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F) is a 40-item PRO questionnaire which evaluates fatigue
and its impact upon daily activities [23]. The scoring scheme
includes physical (PWB), emotional (EWB), social (SWB) and func-
tional (FWB) well-being domains as well as the fatigue subscale
domain (FS). These ﬁve scales together add up to the total FACIT-F
score which ranges from 0 to 160 with higher values representing
better well-being. Other measures of fatigue such as Fatigue Sever-
ity Scale (FSS) and Chronic Fatigue Screener (FSS) have been used in
patients with CH-C [28–30]. However, most recent studies of SOF
regimens have used the FACIT-F for assessment of fatigue.
Finally,  the WPAI:SHP questionnaire is a validated PRO instru-
ment where participants are asked to evaluate impairment in
their daily activities and work productivity associated with a spe-
ciﬁc health problem [24]. In the SOF research studies of patients
with HCV, participants were speciﬁcally asked about the impact of
their HCV infection on their work productivity and their ability to
perform their daily activities. In the WPAI:SHP, the work impair-
ment domain is a sum of impairment in work productivity due to
absenteeism and impairment due to decreased productivity while
working (presenteeism). This domain is assessed only in those who
report being employed at the time of completing the questionnaire.
The activity impairment domain represents impairment in daily
activities other than work and is assessed in all participants regard-
less of their employment status. Unlike the other PRO instruments
discussed, higher WPAI scores lower work productivity or activity.
In fact, the minimum possible value of 0 represents no impairment
in work productivity or daily activities while the value of 1 repre-
sents complete inability to work or perform those activities [24].
3.  Historical data on HRQOL and work productivity in
patients  with hepatitis C
It is important to keep in mind that, prior to the initiation of
treatment, patients with CH-C appear to already experience impair-
ment of their HRQOL. In fact, one of the initial studies of HRQOL
in CH-C reported that 5 out of the 8 domains of the SF-36 were
signiﬁcantly impaired before anti-HCV therapy even began. Most
impairments were noted in the domains measuring role physical,
general health and social functioning [33]. There is also evidence
that severity of liver disease as documented by presence of cirrhosis
further worsens HRQOL impairment [32].
In addition to the baseline impairment of HRQOL in patients
with CH-C, treatment regimens can have additional PRO burden.
As discussed previously, until recently, the standard treatment for
HCV included pegylated interferon (PEG-IFN) and RBV. These regi-
mens were found to be limited in the number of patients that could
be treated due to the substantial side effects and the numerous co-
morbid conditions in patients with CH-C which contraindicated the
use of IFN treatment (anaemia, autoimmune disorder, renal dys-
function, cardiovascular disease, psychosis/bipolar disease, severe
lung disease, substance abuse) [31]. Additionally, IFN and RBV-
related side effects had substantial negative impact on HRQOL and
other PROs. Over the past 2 decades, a number of authors have
reported on the impact of IFN-based therapy on patients’ HRQOL
[31–37].
In one of the initial studies of HRQOL during treatment with PEG-
IFN + RBV, the mean scores for SF-36 scales declined rapidly after
treatment initiation with very signiﬁcant decreases noted in the
domains of role physical, role emotional, vitality and social func-
tioning. On the other hand, after treatment completion, the HRQOL
scores slowly improved, especially for those who  achieved SVR [33].
In addition to this study, a number of other investigators have
assessed the impact of CH-C and its treatment on HRQOL [31–36].
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ne important issue is the concept of clinically relevant changes
n HRQOL scores. In fact, a systematic review of clinical trials
f patients with CH-C have documented the minimal clinically
mportant difference (MCID) for different aspects of HRQOL [34].
CID denotes the changes in HRQOL scores that are clinically
mportant rather than just statistically different. Therefore, MCID
nforms practitioners on how to interpret HRQOL score changes
ver time [34]. After a thorough review from 1990 to 2004, these
nvestigators used 15 articles that studied HRQOL in patients with
CV and compared the results to healthy controls. The ﬁndings
f this review indicated that patients do indeed have a decreased
RQOL prior to treatment especially in the areas of role physical,
ole emotional, and general health. Based on further review and
he input from an expert panel, the investigators determined that
itality was the most comprehensive domain for patients suffering
ith HCV and that a MCID score of 4.2 (range 3–5) on this scale
as the cut-off that should be used when determining the impact
f HCV treatment [34].
Further  studies have investigated the impact of anaemia
nd depression occurring during IFN/RBV treatment on HRQOL
32,35,36]. In one such study, investigators found that treatment-
nduced depression, which increased for the ﬁrst 20 weeks of
reatment, as well as the presence of anaemia both negatively
ffected HRQOL scores. Nevertheless, HRQOL scores improved
tarting 24 weeks after the completion of therapy. From the results
f their multivariate analysis, the researchers found that the impact
f depression on a patient’s HRQOL was so strong that many vari-
bles that were initially found to be signiﬁcant were no longer
igniﬁcant once depression was introduced into the multivari-
te model. Therefore, the authors concluded that treatment for
epression and anaemia must be addressed carefully when treating
atients with PEG/INF [36,37].
In  summary, historical HRQOL data indicates that the HCV infec-
ion itself causes signiﬁcant HRQOL impairment. This impairment
s further ampliﬁed by the side effects of IFN and RBV treatment,
articularly due to the effects of anaemia and depression, both of
hich can affect the mental health domains of HRQOL as well as
atigue, vitality physical and social aspects of HRQOL.
.  Health utilities
Health  utilities are deﬁned as cardinal values representing the
trength of an individual’s preferences for speciﬁc health-related
utcomes – 0 is death and 1 is perfect health. Measuring health
tilities involves two main steps: deﬁning a set of health states
f interest and valuing those health states. The use of health utility
easurements has become popular in discussing health economics
25,26].
There are a number of studies reporting health utility assess-
ent in patients with chronic hepatitis C. In one such study,
nvestigators used several measures of health utilities (HUI2, HUI3,
F-6D and time trade off) to assess patients’ preferences. Addition-
lly, the impact of SVR on health utilities was assessed [37]. All
atients received IFN/PEG-IFN with or without RBV. The results
howed that patients who reached SVR had signiﬁcantly better
ealth utility scores. After adjusting for known confounders (age,
ex, ethnicity, marital status, comorbidity, severity of impairment),
he main utility outcome of HUI-3 (levels of functioning on vision,
earing, speech, ambulation, dexterity, emotion, cognition, and
ain) was affected by viral factors not by the host factors [37].
In  another recent study, using the same measurement tools,
nvestigators determined that CH-C patients who  had sustained
iral clearance had the highest utility scores while those with late
dvanced stage liver disease (cirrhosis and liver cancer) had the
owest utility scores [27]. In contrast, these investigators found that
ost factors such as age, lower income, unattached marital status,er Disease 46 (2014) S186–S196
and  high comorbidity were strongly associated with impairment in
health utilities [27].
In  the most recent study of health utilities in CH-C, researchers
used SF6D to assess health utilities in patients with CH-C and
treatment with SOF-based regimens [38]. The results of the study
showed that health utilities were only minimally impacted with
SOF + RBV treatment when compared to an interferon based treat-
ment regardless of the duration of treatment. Also, results clearly
showed that the utility scores for patients treated with SOF + RBV
regimen were superior to those treated with IFN + RBV. Patients
who achieved SVR, regardless of the treatment regimen, showed
improvement in their SF6D utility scores 12 weeks post treatment,
again validating the results of prior studies [38].
In summary, health utility assessment of patients with CH-C
showed lower patient preference scores prior to treatment, which
worsened with severity of liver disease. Although interferon-based
regimens were associated with signiﬁcant impairment, newer IFN-
free regimens seem to minimally impact health utility scores. As the
newer IFN-free and RBV free regimens for treating CH-C are devel-
oped, patient preference scores are expected to further improve.
5.  PRO assessment for sofosbuvir regimens
The details of SOF regimens that led to the approval of reg-
imens containing this drug are described elsewhere [3,40–43].
Furthermore, the efﬁcacy results of interferon-free and ribavirin-
free regimens with the combination of SOF and ledipasvir (a NS5a
inhibitor) in CH-C have recently been published [44]. In the next few
paragraphs, we will review the current PRO data from SOF contain-
ing regimens that have been fully published [39,45–47]. Although
not fully published, the preliminary results of SOF + LDV regimens
on PROs have also been recently presented and will be summarized
[48,49].
5.1. FISSION study
The  FISSION trial was  a randomized, open-label, active-control
study in treatment naïve patients with HCV genotype 2 and 3
infection comparing 12 weeks of treatment with sofosbuvir plus
ribavirin to peginterferon alfa-2a and ribavirin for 24 weeks.
Patients were enrolled at 97 sites in the United States, Australia,
New Zealand, Italy, Sweden, and The Netherlands from December
2011 to May  2012, and randomly assigned by a centralized system
in a 1:1 ratio to the two  treatment groups. Sofosbuvir was  admin-
istered orally at a dose of 400 mg  once daily along with ribavirin
1000–1200 mg/day administered orally as a divided dose (1000 mg
daily in patients with a body weight of <75 kg, and 1200 mg daily
in patients with a body weight of ≥75 kg). The dose of ribavirin for
patients in the peginterferon-ribavirin group was 800 mg  daily in
2 divided doses. Randomization was  stratiﬁed according to HCV
genotype (2 or 3), screening HCV RNA levels (<6 log10 IU/mL or
≥6 log10 IU/mL), and the presence or absence of cirrhosis [3].
The PRO assessment in FISSION was limited to HRQOL assess-
ment with SF-36. Results of HRQOL data from FISSION showed that
baseline scores did not differ between the two study arms. How-
ever, at the end of treatment (week 12 for the SOF + RBV arm and
week 24 for the PEG-IFN + RBV arm), both physical and mental sum-
mary scores of SF-36 were signiﬁcantly higher in patients treated
with SOF + RBV. Furthermore, the majority of the scales of SF-36
showed signiﬁcantly smaller decrements in the scores of SOF + RBV
as compared to the PEG-IFN + RBV group. At week 12 follow-up,
there was no difference in HRQOL between the study arms and from
baseline. In multivariate analysis, depression, insomnia, fatigue
and anaemia were all associated with lower HRQOL. However,
after adjustment for clinical confounders, receiving SOF rather than
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EG-IFN was associated with higher SF-36 summary scores (better
RQOL) at the end of treatment [45–47].
.2. POSITRON study
The  POSITRON trial was a blinded, placebo-controlled study
hat compared 12 weeks of sofosbuvir and ribavirin with a match-
ng placebo in patients who had either a documented inability to
eceive interferon therapy due to prior intolerance; a medical con-
ition precluding therapy with an interferon; or an unwillingness
o be treated with interferon [40]. Patients were enrolled at 63
ites in the United States, Canada, Australia, and New Zealand from
arch 2012 to May  2012, and were centrally randomized in a 3:1
atio to receive either active treatment or placebo. Randomization
as stratiﬁed by the presence or absence of cirrhosis. Sofosbuvir
as administered orally at a dose of 400 mg  once daily. Ribavirin
as administered orally twice daily, with doses determined by
ody weight (1000 mg  daily in patients with a body weight of
75 kg, and 1200 mg  daily in patients with a body weight of ≥75 kg).
lacebo treated patients received matching sofosbuvir placebo and
ibavirin placebo [40].
The  PRO assessment in POSITRON was also limited to SF-36
uestionnaire. Interestingly, when compared directly, there was  no
ifference in HRQOL observed between those receiving SOF + RBV
s compared to those receiving placebo at all time points. However,
hen scores were compared for each arm separately to their own
espective baseline scores, signiﬁcant drops in HRQOL scores were
bserved in those receiving SOF + RBV but not in those receiving
lacebo. Nevertheless, after 4 weeks of follow-up, no differences
ere observed between the study arms. In the multivariate analy-
is, depression was again found to be a major predictor of HRQOL
mpairment at all time points. Additionally, fatigue was associ-
ted with lower PCS scores, and insomnia was associated with
ower MCS  scores at certain time points. Furthermore, insomnia
as found to be a major predictor of larger drops in HRQOL dur-
ng treatment while at the same time, depression was found to be
ssociated with larger drop in role emotional [45–47].
.3.  NEUTRINO study
The  NEUTRINO was a single-arm open-label phase 3 clinical
rial where patients received a 12-week regimen of sofosbuvir,
eg-interferon alfa-2a and ribavirin. For this study, only treatment-
aive patients with HCV genotype 1, 4, 5, or 6 (of whom 98% had
enotype 1 or 4) were enrolled [3].
The PRO assessment included HRQOL assessment with SF-36
nd CLDQ-HCV, fatigue assessment with the FACIT-F question-
aire and work productivity assessment with the WPAI:SHP. These
uestionnaires were prospectively implemented at baseline prior
o treatment and at 12 weeks at the end of treatment. Further-
ore, patients completed questionnaires 4 weeks post treatment
16 weeks after initiation of treatment). However, only those with
ndetectable HCV RNA at week 16 (4 weeks post treatment) were
equired to attend subsequent visits and completed questionnaires.
On the last day of treatment with PEG-IFN + RBV + SOF (week 12
f treatment), substantial decrements in a majority of PRO scores
ere noted. Moreover, these decrements were similar to the scores
rom historical controls treated with PEG-IFN + RBV. Nevertheless,
t the end of 12 weeks of follow-up, the PRO scores either returned
o their baseline values or were signiﬁcantly higher than the base-
ine scores. Improvement in the work productivity score was also
oted and was found to be attributed solely to the improvement in
he presenteeism component while the absenteeism component
as close to that observed at baseline. Finally, achieving SVR-12 is
ssociated with improvement of some aspects of PROs [45–47].er Disease 46 (2014) S186–S196 S189
5.4. FUSION study
The  FUSION study was  a blinded, active-control study that eval-
uated 12 weeks and 16 weeks of sofosbuvir and ribavirin in patients
who had previously failed an interferon-containing regimen [42].
Patients were enrolled at 67 sites in the United States, Canada, and
New Zealand from May  2012 to July 2012, and randomized 1:1 to
either 12 weeks of sofosbuvir and ribavirin followed by 4 weeks
of matching placebo; or 16 weeks of sofosbuvir and ribavirin. Ran-
domization was  stratiﬁed by the presence or absence of cirrhosis
and HCV genotype 2 or 3. Sofosbuvir was  administered orally at a
dose of 400 mg  once daily. Ribavirin was  administered orally twice
daily, with doses determined by body weight (1000 mg daily in
patients with a body weight of <75 kg, and 1200 mg daily in patients
with a body weight of ≥75 kg).
PRO assessments were similar to NEUTRINO with 4 question-
naires administrated at baseline, during the study (weeks 4, 12 and
16) and at the follow up 4 and 12 [40]. There were no differences
in any of the PRO metrics at any time point between the 12 weeks
and 16 weeks duration arms of receiving SOF + RBV. These results
indicated that the addition of 4 extra weeks of SOF + RBV did not
have additional negative impact on PROs.
Comparing PRO scores to the patients’ baseline scores, some
mild decrements were noted in fatigue, HRQOL, and work produc-
tivity (presenteeism and absenteeism) areas at treatment weeks
4, 12, and 16 in both arms of the study. By week 4 of follow-up,
regardless of regimens, all scores returned to their baseline val-
ues, and some domains showed further improvement. Again, some
aspects of PROs improved in those with SVR-12 [45–47].
5.5.  VALENCE study
The  VALENCE study was conducted with a SOF/RBV regimen
in genotype 2 and 3 patients who  were either treatment naïve or
treatment experienced with an IFN based treatment (58%). The 91
patients with genotype 2 HCV were treated for 12 weeks with the
end goal of SVR 12 weeks post treatment. The 328 patients with
genotype 3 HCV each received treatment or a placebo for 12 weeks
but due to additional phase 3 evidence available before the end of
the trial, the study was un-blinded for this group of patients and
treatment for all genotype 3 patients was extended for 24 weeks
[43].
PRO assessment in the VALENCE study was  similar to the FUSION
study (SF-36, FACIT-F, CLDQ-HCV and WPAI:SHP). Comparable to
the results of the FUSION study, all arms of the study had a moderate
decrease in the PRO metric scores during treatment with SOF + RBV.
Nevertheless, by week 12 of follow up, scores either returned to
baseline or improved. In fact, patients who experienced SVR-12,
regardless of the treatment arm, experienced signiﬁcant improve-
ment of their PROs [39].
It  is important to note that in all these clinical trials, the PRO
questionnaires were administered prior to discussion of lab results
including HCV RNA or patient’s response to treatment [3,40–43].
6.  Predictors of PROs in FUSION, FISSION, POSITRON,
NEUTRINO and VALENCE
In  separate multivariate analyses of these studies, the indepen-
dent predictors for lower PRO scores were consistently found to be
a history of depression, fatigue, anxiety, insomnia, cirrhosis and
history of treatment failure [39,45–47]. A point of interest was
that adverse events during treatment were signiﬁcant predictors of
lower PRO’s during treatment, particularly gastrointestinal symp-
toms which occurred up to 12 weeks post treatment [39]. This
indicates that regimens with minimal side effects can have sub-
stantial PRO advantage over regimens with potential side effects.
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.1. ION 1 and 2 studies
The  efﬁcacy and safety data of SOF + LDV with or without RBV
ere recently published [41,42,44]. Furthermore, the preliminary
esults of the regimens containing SOF + LDV with or with RBV
IONs) on PROs were also recently presented [45,48,49]. Brieﬂy,
he results provided assessment of PROs (SF-36, CLDQ-HCV, FACIT-
, WPAI) in CH-C patients treated with SOF + LDV regimens. These
our PRO questionnaires were administered at baseline, during
nd post-treatment to genotype 1 CH-C subjects treated with
OF + LDV + RBV or SOF + LDV for 12 or 24 weeks (ION-1 and 2 tri-
ls). Patients and providers were blinded to the HCV RNA results at
he time of completion of the questionnaires [41–43,47–49].
Throughout treatment, most of the PRO scores, including scores
elated to HRQOL, fatigue, and work productivity, were superior
or the RBV-free regimens (SOF + LDV) as compared to RBV-
ontaining regimen (SOF + LDV + RBV). Additionally, as compared
o their own baseline, patients who received the RBV-containing
OF + LDV + RBV regimen experienced mild decrements in PRO
cores, while on the other hand, patients who received RBV-free
egimens actually experienced improvement of their PRO scores.
his improvement was observed as early as 2 weeks after treatment
nd maximized by the end of treatment. Regardless of the treat-
ent regimen, patients who achieved sustained viral eradication
ad signiﬁcant improvement of all PROs by week 12 post-treatment
p < 0.001) [48,49].
As previously mentioned, depression, fatigue and anxiety have
een the most consistent independent predictors of PROs at any
ime point [39,45,46,48,49]. These variables as the most impor-
ant predictors of PRO scores were again validated in multivariate
nalysis of ION 1, and 2 PRO data.
. Summary
The results of the PRO studies of the new IFN-free regimens as
ompared to the IFN-containing are very favourable. In fact, the
RO studies indicated that patients undergoing treatment with
OF + RBV experience minimal decrements in their PRO scores dur-
ng treatment. Achieving SVR-12 with these regimens is associated
ith improvement of PROs.
Preliminary PRO results from IFN-free and RBV-free regimens
ith SOF + LDV show further improvement of PRO scores during
reatment. Furthermore, SVR-12 is again associated with signiﬁcant
mprovement of PROs. These results are extremely signiﬁcant as
hey indicate better tolerability of these new regimens, which could
otentially lead to better compliance to treatment with very low
rop-out rates due to side effects. The increase in compliance may
ave contributed to the high SVR rates reaching 95–98% for the
FN-free RBV-free regimen with SOF + LDV.
In addition to SOF + LDV regimens, a number of other interferon-
ree regimens are being developed. These regimens include a
OF + SIM combination, a ﬁxed-dose combination of the protease
nhibitor ABT-450 and ritonavir co-formulated with the NS5A
nhibitor ombitasvir (ABT-267), as well as the non-nucleoside
olymerase inhibitor dasabuvir (ABT-333) and Daclatasvir-based
egimens are now in the development phase with fully published
ata [50–57]. Unfortunately, at the present time, fully published
RO data related to these regimens and evidence supporting their
mpact on patient experience are not available. Nevertheless, we
trongly urge for the assessment of PROs in parallel to the assess-
ent of the efﬁcacy and safety of these regimens. We  believe thathis multi-prong approach to assessment of clinical and patient-
eported outcomes will provide the most comprehensive and
omplete data regarding the impact of these new anti-HCV regi-
ens on patients and their well-being.er Disease 46 (2014) S186–S196
8.  Economic assessment
Another  aspect of the assessment of new anti-HCV regimens
is related to economic considerations. However, it is important
to remember that the economic assessment goes beyond just
the cost of the medication. In fact, economic analysis should
also encompass the cost of monitoring during treatment, cost
of side effects management, as well as the cost associated with
the management of HCV-related advanced liver disease and
its complications. Furthermore, there are potential costs asso-
ciated with the extrahepatic manifestations of untreated HCV
and the indirect cost to society in loss of worker productivity.
Therefore, the following sections present the recently com-
pleted analyses investigating the economic impact of hepatitis C
[58–93].
9. Health care economic burden of CH-C
The economic burden of CH-C is estimated to be enormous. In
one study, investigators found that the cost of non-cirrhotic liver
disease associated with CHC was  estimated at around $17,277 per
patient per year of treatment (pppy) while the cost of compensated
cirrhosis related to CH-C was estimated to be around $22,752 pppy
and the costs of CH-C with end stage liver disease, hepatocellular
carcinoma or liver transplantation were estimated to be $59,995,
$112,537 and $145,000 pppy, respectively [58–60].
The economic implications of these data should be viewed in the
context of HCV disease progression. It is estimated that for every
one hundred individuals who  are acutely infected with HCV, 75–85
people will develop a chronic HCV infection, 60–70 people will
develop a chronic liver disease, 20–25 patients will develop cirrho-
sis and 1–5 people will die of end stage liver disease or liver cancer
related to CH-C [60]. Furthermore, the number of people infected
in the United States is estimated to be around 3 million. Given the
underrepresentation of certain groups with high prevalence of HCV
from the initial NAHNES studies from the United States, the true
prevalence of HCV in the U.S. can be estimated to be approximately
5–7 million people [55,59,73]. If one considers the prevalence of
HCV (even the conservative estimates), the progression of HCV-
related liver disease, and the cost of each state of health related
to CH-C, the economic burden (health care costs) of CH-C in the
U.S. is approximately $9.60 × 1012 annually [59,60]. If one assesses
the economic burden of HCV globally where 170 million people are
estimated to have chronic hepatitis C, the global economic burden
of HCV can be tremendous.
It  is also important to remember that in the United States,
HCV-related liver disease is disproportionately affecting the baby
boomers born during 1945–1965. It is estimated that this birth
cohort will be increasingly affected by the consequences of HCV-
related liver disease. To appreciate the growing economic impact
of CH-C in the U.S. over the next few decades, potentially related to
the maturation of HCV-related liver disease in the baby boomers,
trend analyses of health care utilization related to CH-C have been
conducted. One such study of the “birth cohort” suggested that the
number of these patients with CH-C has risen from 983,000 in 2007
to 1.19 million in 2009. These individuals account for 75.0% of all
patients with HCV, 83.7% of patients with advanced liver disease,
and 79.2% of the costs associated with HCV in 2009. Also, non-
pharmacological costs in this study grew from $7.22 billion to $8.63
billion during the same time frame, with the majority of growth
derived from the 60,000 new CH-C patients developing advanced
liver disease. The projection model from this study estimated that
the total advanced liver disease population with CH-C will grow
from 195,000 in 2008 to 601,000 in 2015, with 73.5% of new cases
of advanced liver disease from patients undiagnosed as of 2008
[68].
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In another modelling study, investigating all cause and incre-
ental per patient year cost of patients with CH-C treated in a
anaged care organization, patients with HCV had the annual all
ause medical costs that were almost twice as high as those without
CV. In addition, patients with HCV-related advanced liver disease
ad dramatically higher costs. These ﬁndings translated to an incre-
ental all cause cost of more than $9000 pppy and $27,000 pppy
or the patients with advanced liver disease [73].
In the United States, one group of CH-C patients that may  be
isproportionately affected by this economic trend is the group
overed by Medicare, the nation’s insurance program for those 65
ears and older and those with special medical conditions [59].
s more and more baby boomers become Medicare eligible, the
conomic impact of CH-C in the Medicare program becomes sig-
iﬁcant. In a recent study of patients with CH-C, it was estimated
hat Medicare incurs an annual cost of $23,000 for inpatient care
nd $584 for the outpatient care per patient claim with this group
ccounting for 67.6% of all care episodes, which totals over $15
illion annually [58–62].
During  treatment of CH-C, there are baseline costs of CH-C as
ell as costs associated with anti-HCV drugs and the costs asso-
iated with clinical and laboratory monitoring during treatment.
n fact, these costs (laboratory monitoring, clinic visits, treatment
f side effects and extra-hepatic manifestations) can occur regard-
ess of whether or not SVR is achieved. As previously described,
ide effects are common with the regimens that include PEG-IFN,
BV and ﬁrst generation DAAs. In fact, the most common side
ffects are anaemia, thrombocytopenia, rash, and depression. Man-
gement of these side effects could result in substantial costs.
ased on a recent study, the extra costs associated with treating
hese side effects were $37,000 for anaemia, $22,000 for throm-
ocytopenia, $11,000 for rash and $22,000 for depression [63,64].
evertheless, the costs of managing these side effects may  vary
rom country to country and the type of health insurance used.
or example, in Canada, a similar study found that the cost of
naemia was $10,804 (CDN), the cost of managing rash was $77
CDN) and the cost for managing depression was $261 (CDN)
64].
In addition to the cost of managing side effects, there are a
umber of laboratory tests that are done for safety monitoring or
ssessing response guided therapy of the older regimens. Further-
ore, the cost associated with physician extenders, providers and
ther ofﬁce staff to manage and support patients during treatment
an be substantial.
Although these costs can vary in different regions of the world,
t is important to note that the total cost of the regimens must
ot only include the cost of the drugs, but also the costs of the
equired laboratory monitoring, clinic visits and the cost of side
ffects management. Additionally, one must also consider the costs
ssociated with futile treatment which then requires subsequent
reatment which incurs additional costs.
There is now increasing evidence that HCV is a systemic dis-
ase with both hepatic and extrahepatic manifestations. Most of
he studies assessing the clinical, economic and PRO impact of HCV
nfection have focused on the hepatic manifestation of HCV and its
ssociated complications (cirrhosis, liver cancer and liver-related
ortality). It is important to note that in addition to liver-related
ost, and the total cost of treatment, HCV also has signiﬁcant costs
ssociated with its extrahepatic manifestations (fatigue, vasculitis,
tc.). Unfortunately, the true prevalence and economic impact of
hese extrahepatic manifestations have not been estimated. Nev-
rtheless, we strongly believe that the economic burden of HCV
elated to extrahepatic manifestations, and the indirect cost of HCV
o society (worker productivity) should be added to the cost of HCV-
elated liver disease. It is with this comprehensive approach to the
ost of care for HCV that we can provide a fair assessment of theer Disease 46 (2014) S186–S196 S191
true  impact of this disease and the true value of highly curative
treatment regimens.
10.  Indirect costs to the society
CH-C affects patients in their fourth or ﬁfth decade of life, a
time when many people are reaching the most productive years
of their lives. In fact, many CH-C patients incur a signiﬁcant drop in
work productivity, which is primarily associated with HCV-related
fatigue. A recent study assessed the indirect costs of lost productiv-
ity for both the patient and the caregiver. The investigators found
that when a patient is originally diagnosed with HCV they miss, on
average, 0.43 days/annotated as mean days lost per patient month
(days/ppm) with a range of 0–30 days. As disease progressed to
HCC or transplant, this impairment worsens [HCC: 0.57 days/ppm
(0–5), transplant: 1.11 days/ppm (0–15); respectively]. Although
caregivers are less affected by the diagnosis of HCV in earlier stages
of liver disease, this trend worsens when more advanced liver dis-
ease develops. The impact of HCV on patients and their caregivers
is important when calculating the economic burden of HCV but is
rarely considered [63].
In addition to this study, other researchers have reported on
work productivity of patients with HCV [69–72]. Using data from
the US National Health and Wellness Survey, a recent study com-
pared workers with HCV to workers without HCV. After propensity
score matching, the investigators found that patients with HCV
were signiﬁcantly less likely to be in the labour force, had higher
levels of absenteeism (1.61 times higher), presenteeism (1.24 times
higher), overall work and activity impairment (1.24 times higher)
[69]. In another similar study, employer records were used to obtain
the productivity data. These results conﬁrmed again that HCV has
a tremendous negative impact on work productivity [71]. Another
study using the data from the 2012 US National Health and Well-
ness survey conﬁrmed the same trend of impaired work and activity
while experiencing increased resource utilization [72].
In  addition to the impact of HCV-related liver disease, treatment
of CH-C with anti-viral regimens can also impact work productivity.
One such study examined the impact of IFN based treatment on the
absenteeism and work productivity among employees with HCV.
Investigators found that employees treated with IFN based ther-
apy actually were less productive and had more absenteeism than
HCV patients not receiving treatment [70]. In contrast, studies using
SOF + RBV showed little impact on worker productivity [39,47]. The
most recent data assessing worker productivity in patients using
interferon-free and ribavirin-free regimen (SOF + LDV) showed
improvement in work productivity (primarily through improved
presenteeism) in patients with CH-C [48,49,69–72]. These new reg-
imens are also associated with high cure rates which improved not
only PROs but also worker productivity [48,49,69–72].
If HCV cure leads to improvement in worker productivity, what
are the estimated indirect costs to the society of not treating these
patients? This is an interesting question that was addressed in a
recent report by the Rand Corporation. In this study, performed
for the UK, the investigators not only conﬁrmed the impact of HCV
on work productivity, but also, through simulation modelling, pro-
vided estimates as to what would happen to the rate of increase
of HCV and the effect of increased treatment on health care costs
and worker productivity [67]. They determined that if HCV was
left untreated, there would be an overall increase in the number
of persons living with HCV infection from around 265,000 in 2010
to 370,000 in 2035 with an estimated increase in healthcare costs,
from £82.7 m in 2012 to £115 m in 2035. Productivity losses were
estimated to rise from £184–367 m in 2010 to £210–427 m in 2035
(using minimum and median wage) [67]. However, if the use of
antiviral treatment was  quadrupled then the projected increase in
the prevalence of HCV would be halted and actually start to decline
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y 2035. This increase in treatment rates would also reduce the
umber of those with decompensated cirrhosis and hepatocellular
arcinoma from an estimated 17,000, under the current treatment
ssumption, to 12,000 in the increased treatment assumption by
035. The average additional cost of antiviral treatment per annum
etween 2012 and 2035 was then estimated at £43.8 m.  Productiv-
ty losses associated with HCV infection were estimated to range
rom £184–380 m in 2012 but set to increase to £209.7–427 m in
035 if HCV was  left untreated, but if treated then the average
ain in productivity per annum is estimated at £73.3 m per annum.
he study concluded that this estimated gain in productivity by
uadrupling the treatment rates would clearly outweigh the addi-
ional investment required to cover the additional cost of antiviral
reatment [67].
Although  some interesting studies related to work productivity
f HCV infected patients are being published, much more research
s required to provide a better understanding of this indirect cost
f HCV to society.
1.  The impact of successfully treating CH-C
As noted in the previous sections, if CH-C is left untreated or
reated unsuccessfully, it can potentially create tremendous cost
o the society. Therefore, questions have been raised as to how
any people have to be treated in order to affect the disease burden
nd thus reduce its costs to society. Several groups of investigators
ave studied this important but challenging issue [74–76]. In Eng-
and, researchers found that in order to reduce the number of liver
elated deaths by 80%, treatment would need to increase 3 fold,
hich would only occur if at risk pool of patients increased 4 fold
eading to 2.7 fold increase in the number of patients diagnosed and
o an increase in the number of treatment eligible patients by 1.5
old [75]. A similar analysis from Australia also demonstrated the
ame striking ﬁndings [74].
On the other hand, if treatment rates do not change substan-
ially, the number of patients with HCV-related complications will
ise. One study estimated that if the current treatment rates and
revalence of HCV does not change, by 2030, the percentage of
atients with advanced liver disease, HCV-related deaths, HCC-
elated deaths would increase by 20%, 70% and 85%; respectively
68,76].
In addition to treatment rates, the efﬁcacy of treatment regi-
ens can impact future complications of HCV. One study recently
stimated that with better treatment achieving SVR rates of
0–95%, the HCV population could decline 85%, HCV-related mor-
ality including HCC would decrease by 70% while decompensated
irrhosis would decline by 80% [68,76].
Both these studies point out the importance of not only efﬁcacy
ates but also treatment rates in the community. In order to reach
his meaningful reduction in the burden of CH-C, a multi-faceted
pproach is required. A successful approach would ﬁrst establish
n effective screening and identiﬁcation program for HCV which
ould link HCV positive patient directly to care. Then treatment
egimens with high efﬁcacy, low side effects and better tolerabil-
ty must be made available to most of the HCV-infected patients.
ith this process in place, patients’ adherence to the regimens may
mprove, potentially leading to an important reduction in HCV bur-
en. Nevertheless, access to care for HCV is not only related to the
fﬁcient identiﬁcation of the infected patients but also to linking
hem to care and to the cost of drugs and the cost-effectiveness of
reatment regimens.2.  Cost of therapy in the era of DAAs
The ﬁrst generation DAAs (protease inhibitors) have been asso-
iated with SVR rates ranging from 37.2% for non-responders toer Disease 46 (2014) S186–S196
73.9%  for treatment naïve patients [60,61]. In fact, these rates have
been found to be lower in the community setting because of sub-
stantial side effect proﬁles.
In addition to the efﬁcacy and effectiveness data, there are a
number of studies reporting the cost of these regimens in the con-
text of achieving SVR. In one study, costs of obtaining SVR with
these regimens ranged from D 66,885 to D 120,350 depending on
which triple therapy combination (boceprevir or telaprevir/PEG-
INF/RBV) was  used. These costs were lower for patients who  were
compliant with treatment [81]. In another study using data from the
French national hospital database, investigators determined that
the discounted lifetime costs increased with the severity of ﬁbrosis
at diagnosis and that treatment with triple therapy increased dis-
counted lifetime costs which were 20% (F2), 28% (F3) and 79% (F4)
[79].
A number of other studies have reported the real world cost
of treating HCV with triple therapy. In one study, out of a total of
147 patients who received TVR triple therapy, 44% obtained SVR
with a median cost of $188,859 per SVR 24. The unexpected ﬁnding
was that almost half the costs spent were on patients not obtain-
ing SVR, as well as the cost associated with the management of
adverse events and cost associated with the premature discontinu-
ation of treatment [81]. In another study, Sethi et al. found that the
mean cost of treatment was $172,889 for treatment with a pro-
tease inhibitor. But they also found that the cost of side effects
and the low SVR rate (49%) added substantial cost to treatment. In
this study, the largest contributor to costs was thrombocytopenia,
which more than doubled the cost of therapy, with the partial/non-
responder group also incurring almost twice the costs of therapy
as the treatment naïve and relapsers [82].
The cost-effectiveness of the second generation DAAs has
also been recently addressed. One such study compared the
cost-effectiveness of SMV/PEG-INF2a/RBV to SOF + PEG-INF2a/RBV.
Results from this study reported that the cost of SMV  therapy
was $9882 (8%) more than the cost of SOF regimen ($125,950 vs.
$116,068) per successfully treated patient [84]. These investigators
also presented the cost comparisons for obtaining SVR between
these therapies in treatment-naïve G1 patients with and without
cirrhosis. They again found that SMV  based therapy costs for each
successfully treated patient exceeded the SOF based therapy by 6%
($119,878 vs. $113,148, respectively) in patients without cirrhosis
(F0–F3) and 20% ($166,165 vs. $132,592, respectively) in patients
with cirrhosis (F4) [84,85]. In another study, the same cost trends
were found in patients co-infected with CH-C and HIV where the
cost of SMV  based therapy exceeded the cost of SOF  based therapy
by 13% for each successfully treated patient ($155,868 vs. $135,830,
respectively) [86].
The  costs of the ﬁrst generation DAA regimens were compared
to the cost of SOF regimens for the treatment of HCV. Investi-
gators compared the cost of SOF based regimen to the cost of
triple therapy (BOC/PEG-IFN/RBV or TVR/PEG-IFN/RBV) in CH-C
patients [89,90]. Using a Markov model for cost effectiveness con-
taining the different combinations of treatment regimens for the
different subpopulations in terms of HCV genotype, presence of
HIV co-infection status and previous treatment experience, they
found that in HCV G1 patients without HIV infection SOF/PR treat-
ment resulted in 4.3LY, & 5.0LY or 8.0LY gained when compared to
telaprevir/PR, boceprevir/PR or PR; respectively. In patients with
HCV G4,5,6 (HIV negative), SOF treatment gained 9.2 years com-
pared to PEG-IFN/RBV, which is estimated to be closer to the life
expectancy of the general population. For the HCV G1,2 HIV co-
infected patients, the estimated life years gained when treated
with SOF in PEG/INF eligible patients was 11.8 years and 5.0 years,
respectively. In the co-infected patients with G1 and G3 not PEG/INF
eligible, 15.3–18.6 years were gained with the use of SOF, which
gives SOF a therapeutic efﬁciency of 94.3–92.4% of the general
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opulation life expectancy. Therefore, when SOF treatment was
ompared to BOC and TEL containing treatment for HCV G1, a QALY
stimate of 12,238D /QALY and 16,495D /QALY were gained while
5,206D /QALY was gained for the HCV–HIV co-infected patients.
he incremental undiscounted costs in HCV G1 ranged from 8854D
o 18,565D [89,90]. These data clearly show the superiority of SOF
ontaining regimens as compared to the ﬁrst generation DAAs.
The  long term outcomes in treatment naive patients with HCV
enotypes 1/4/5/6 who were treated with SOF/PEG-INF2a/RBV and
OF/RBV in treatment naïve (TN) and treatment experienced (TE)
n GT2 and GT3 patients in the UK have also been investigated. After
erforming Markov modelling for patients who  received either 12
r 24 weeks of treatment, researchers found that the QALY’s gained
anged from 4191 pounds for GT1 TN patients treated with TVR to
2,070 pounds for GT1TN treated with SOF based treatment. Treat-
ent experienced patients (GT2TE and GT3TE) had the other lowest
ALY’s gained (5608 pounds and 4849 pounds respectively). The
esearchers concluded that treatment with a SOF based regimen
ith or without interferon was appropriate even for patients with
irrhosis with no current treatment option [66].
In addition to genotypes 1 and 2, patients with HCV genotype 3
ave also been studied. Currently, HCV genotype 3 is considered the
ost difﬁcult cohort to treat. In a recent study, cost-effectiveness of
OF and RBV for 16 and 24 weeks was assessed. These investigators
etermined that 58.1% of these patients would achieve SVR with
ost per QALY gained ranging from £6585 to £ 30,244 [87].
In addition to the above economic analysis, the cost-
ffectiveness of these regimens in CH-C patients with early liver
isease has also been assessed. In one study, these regimens were
ound to be cost effective for patients with advanced liver disease
ﬁbrosis stage > F2) with ICER of £ 37,900/QALY gained, However,
he ICER was higher for patients with early ﬁbrosis (stage of F0-1)
t £103,500/QALY gained [88]. In contrast, the cost-effectiveness of
nterferon-free regimens on clinical and cost outcomes in patients
ith C-HC genotype 1 has also been recently reported. In fact, this
tudy concluded that treating all HCV patients regardless of the
tage of their liver disease with IFN-free regimens was  cost effec-
ive. Using 4 treatment strategies [triple therapy (IFN, RBV, DAA)
ith staging-guidance or treat all, and oral IFN-free regimen with
taging-guidance or treat all] in a Markov model scenario (a 50
ear old and a 50% cost increase) initiating treatment at ﬁbrosis
tages F2–F4, treatment of all patients with an oral IFN-free regi-
en was the most cost-effective strategy. This strategy had an ICER
f $15,709/QALY at baseline cost of oral therapy. The ICER remained
elow $50,000/QALY in the sensitivity analyses for baseline and
50% cost for the oral therapy scenarios. The treat all strategy was
lso the most effective strategy and was associated with the lowest
isk of developing advanced liver disease [80].
A similar study investigated the cost effectiveness of SOF/PEG-
FN/RBV on all patients (treatment naïve, treatment experienced,
o-infected with HCV and patients with cirrhosis whether treated
r not). This group of researchers found that SOF/PEG-IFN/RBV
as more efﬁcacious and less costly than triple therapy with the
rotease inhibitors (boceprevir and telaprevir) across all groups
specially when obtaining SVR [89]. These results have been veri-
ed by others [88–90].
Although  IFN-free regimens have been a signiﬁcant advance in
reating CH-C patients, they still contain RBV with its potential side
ffects. The economic analysis of IFN-free and RBV-free regimens,
sing the combination of ledipasvir/sofosbuvir (LDV/SOF), has also
een studied. Researchers found that patients on the LDV/SOF
ased regimens had the least liver related complications, more
ife years gained and quality adjusted years compared to the other
reatment regimens of SOF/PR and SMV/PR among both treatment
aïve and treatment experienced patients. The authors concluded
hat though these results are very encouraging, a real worlder Disease 46 (2014) S186–S196 S193
analysis  must be completed so that differences between modelling
outcomes and real world outcomes can be ascertained [90,91].
In  addition to SOF + LDV, another IFN-free and RBV-free regimen
uses a combination of SOF + SMV. In a recent economic analy-
sis, the combination of SOF + SIM was assessed for treatment of
interferon (IFN)-ineligible/intolerant individuals with genotype 1
CH-C according to AASLD/IDSA guidance [92,93]. These researchers
determined that a 12 week course of SOF/SMV compared to a 24
week treatment of SOF/RBV yielded lower costs and more qual-
ity adjusted years. In addition, they determined that SOF/SMV
averaged $165,336 and 14.69 QALYs (cost per QALY $11,255) vs.
$243,586 and 14.45 QALYs (cost/QALY $16,857) for SOF/RBV. In
the base-case cost analysis, the SOF/SMV treatment strategy saved
$91,590 per SVR compared to SOF/RBV, which cost $262,046 per
SVR with the results being sustained after sensitivity analysis.
Finally,  in the context of these economic data, it is important to
place the cost of treating of CH-C in the framework of other chronic
diseases. In one study, the value of HCV treatment was  compared
to the treatment costs for 5 other important chronic diseases (Type
2 diabetes, HIV, rheumatoid arthritis, breast cancer with metas-
tasis, and the relapsing multiple sclerosis). This analysis showed
that although CH-C was  the second most prevalent chronic dis-
ease on this list, treatment of CH-C genotype 1 treatment-naïve
patients was  the second least expensive treatment. Furthermore,
treatment of CH-C is the only treatment that provides patients with
cure that can be associated with reducing mortality, morbidity and
their associated costs [94–100].
In summary, the economic analyses of the new anti-HCV reg-
imens are very encouraging. In fact, the most attractive regimens
seem to be interferon-free RBV-free regimens with tremendously
high efﬁcacy, low side effects and short duration of treatment. Real
world scenarios of these new regimens still need to be conducted,
but these results should assist the current stakeholders in deciding
how best to approach treatment from an economic standpoint.
13.  Other future treatments
Currently,  there are several other drug regimens awaiting FDA
approval. These include a NS5A replication complex inhibitor,
daclatasvir in combination with an NS3 protease inhibitor,
asunaprevir for HCV genotype 1b and other HCV genotypes [54,55].
Another regimen consist of a protease inhibitor ABT-450 and a rito-
navir co-formulated with the NS5A inhibitor ombitasvir (ABT-267)
as well as the non-nucleoside polymerase inhibitor dasabuvir (ABT-
333) with or without ribavirin. As noted previously, the SOF  and SIM
combination is also being considered as another all oral regimen.
Although efﬁcacy results for these regimens have been published,
no economic or PRO data has been published [54,55].
14. Summary
There is increasing evidence that HCV-related liver disease has
a signiﬁcant negative impact on patient reported outcomes. This
impairment worsens with liver disease severity and improves after
achieving SVR. These PROs also impact worker productivity, which
leads to a negative impact on society. Additionally, HCV-related
liver disease places a substantial economic burden on patients,
their families and society. Furthermore, there is an increasing
appreciation of HCV as a systemic disease with both hepatic and
extrahepatic consequences. If the PRO and the economic impact
of the extrahepatic manifestation of CV are added to its hepatic
manifestation, its true clinical, PRO and economic impact can be
enormous.
Although the earlier treatment of HCV was associated with sig-
niﬁcant side effects, which negatively impacted patient reported
outcomes, the newer regimens, especially those which are free
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f IFN and RBV cause substantial improvement of PROs during
herapy, which lasts long after achieving SVR. Many studies have
ecently been published dealing with the safety and efﬁcacy of
he new direct antiviral agents [14,3,41–44,54,55,83,84].  Except for
OF-based regimens, not much has been published on the effect of
hese regimens on patient reported outcomes and on their eco-
omic impact.
Economically, several areas have been explored, which includes
he cost of HCV to society as well as the cost of treating or not
reating HCV, and the indirect cost of HCV related lower work pro-
uctivity. Based on the current evidence, the burden of HCV is
remendous and, in fact, may  be underestimated. We  believe that
he economic burden of HCV is underestimated because the eco-
omic impact of extrahepatic manifestations of HCV infection and
he indirect cost of lower worker productivity of these patients have
ot been adequately addressed. The current economic analyses also
rovide evidence that cost per cure of the new regimens for treat-
ng HCV are superior to the cost per cure of the older regimens. As
he new regimens free of interferon and ribavirin are being devel-
ped, the economic analyses of these regimens must follow. The
reliminary economic assessment of these new regimens suggests
hat these regimens are excellent for patients with HCV and a good
eal for society.
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